Abstract
In the last chapter, examples were presented of how lead structures can be discovered by purposefully searching, particularly by using examples from nature or compounds with known modes of action. Even if a large number of natural products and synthetic substances are available, it is not always easy to filter the active molecules out and to assess their value for a given indication. This requires a time-and cost-intensive sorting or screening of enormous substance libraries. By “screening” is meant the more or less specific biological testing of compounds. Although today molecular test systems and cell culture models are practically exclusively used, the cost for testing a compound is between US $2 and US $5. Because typically millions of compounds are tested, a screening campaign can cost a lot of money!
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
General Literature
Blundell TL, Jhoti H, Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1:45–54
Hajduk PJ, Greer J (2007) A decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6:211–219
Jahnke W, Erlanson DA (2006) Fragment-based approaches in drug discovery. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 34. Wiley-VCH, Weinheim
Jones AK, Buckingham SD, Sattelle DB (2005) Chemistry-to-gene screens in Caenorhabitis elegans. Nat Rev Drug Discov 4:321–330
Klebe G (2006) Virtual ligand screening: strategies, perspectives and limitations. Drug Discov Today 11:580–592
Löfås S (2004) Optimizing the hit-to-lead process using SPR analysis. Assay Drug Dev Technol 2:407–415
Siegel MM (2002) Early discovery drug screening using mass spectrometry. Curr Topics Med Chem 2:13–33
Sotriffer C (2010) Virtual screening. In: Mannhold R, Kubinyi H, Folkers G (eds) Methods and principles in medicinal chemistry, vol 48. Wiley-VCH, Weinheim
Vogtherr M, Fiebig K (2003) NMR-based screening methods for lead discovery. In: Hillisch A, Hilgenfeld R (eds) Modern methods of drug discovery. Birkhäusen Verlag, Boston, pp S183–S120. ISBN 376436081X
Special Literature
Hajduk PJ, Sheppard G, Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, Steinman DH, Carrera GM Jr, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen SK, Summers JB, Fesik SW (1997) Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J Am Chem Soc 119:5818–5827
Erlanson DA, Braisted AC, Raphael DR, Randal M, Stroud RM, Gordon EM, Wells JA (2000) Site-directed ligand discovery. Proc Natl Assoc Soc 97:9367–9372
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Klebe, G. (2013). Screening Technologies for Lead Structure Discovery. In: Klebe, G. (eds) Drug Design. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-17907-5_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-17907-5_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-17906-8
Online ISBN: 978-3-642-17907-5
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences
